@article {7079,
	title = {Current therapy guidelines for Waldenstrom{\textquoteright}s macroglobulinaemia},
	journal = {Best Practice and Research: Clinical Haematology},
	volume = {29},
	year = {2016},
	note = {Export Date: 18 February 2017References: Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms (2016) Blood, 127 (20), pp. 2375-2390. , May 19;Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Clinicopathological definition of Waldenstrom{\textquoteright}s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom{\textquoteright}s macroglobulinemia (2003) Semin Oncol, 30 (2), pp. 110-115. , Apr; 
Kyle, R.A., Treon, S.P., Alexanian, R., Barlogie, B., Bjorkholm, M., Dhodapkar, M., Prognostic markers and criteria to initiate therapy in Waldenstrom{\textquoteright}s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom{\textquoteright}s macroglobulinemia (2003) Semin Oncol, 30 (2), pp. 116-120. , Apr; 
Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Update on treatment recommendations from the Third International Workshop on Waldenstrom{\textquoteright}s macroglobulinemia (2006) Blood, 107 (9), pp. 3442-3446. , May 1; 
Dimopoulos, M.A., Gertz, M.A., Kastritis, E., Garcia-Sanz, R., Kimby, E.K., Leblond, V., Update on treatment recommendations from the Fourth International Workshop on Waldenstrom{\textquoteright}s macroglobulinemia (2009) J Clin Oncol, 27 (1), pp. 120-126. , Jan 1; 
Dimopoulos, M.A., Kastritis, E., Owen, R.G., Kyle, R.A., Landgren, O., Morra, E., Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus (2014) Blood, 124 (9), pp. 1404-1411. , Aug 28; 
Vos, J.M., Minnema, M.C., Wijermans, P.W., Croockewit, S., Chamuleau, M.E., Pals, S.T., Guideline for diagnosis and treatment of Waldenstrom{\textquoteright}s macroglobulinaemia (2013) Neth J Med, 71 (2), pp. 54-62. , Mar; 
Ansell, S.M., Kyle, R.A., Reeder, C.B., Fonseca, R., Mikhael, J.R., Morice, W.G., Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines (2010) Mayo Clin Proc., 85 (9), pp. 824-833. , Sep; 
Owen, R.G., Pratt, G., Auer, R.L., Flatley, R., Kyriakou, C., Lunn, M.P., Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia (2014) Br J Haematol, 165 (3), pp. 316-333. , May; 
Buske, C., Leblond, V., Dimopoulos, M., Kimby, E., Jager, U., Dreyling, M., Waldenstrom{\textquoteright}s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2013) Ann Oncol, 24, pp. vi155-vi159. , Oct; 
Owen, R.G., Kyle, R.A., Stone, M.J., Rawstron, A.C., Leblond, V., Merlini, G., Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop (2013) Br J Haematol, 160 (2), pp. 171-176. , Jan; 
Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H., Initial immunoglobulin M {\textquoteleft}flare{\textquoteright} after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study (2004) Cancer, 101 (11), pp. 2593-2598. , Dec 1; 
Treon, S.P., How I treat Waldenstrom macroglobulinemia (2009) Blood, 114 (12), pp. 2375-2385. , Sep 17; 
Treon, S.P., Branagan, A.R., Hunter, Z., Santos, D., Tournhilac, O., Anderson, K.C., Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom{\textquoteright}s macroglobulinemia (2004) Ann Oncol, 15 (10), pp. 1481-1483. , Oct; 
Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom{\textquoteright}s macroglobulinemia: results of WMCTG Trial 03-248 (2007) Clin Cancer Res, 13 (11), pp. 3320-3325. , Jun 1; 
Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity (2006) J Clin Oncol, 24 (13), pp. 2105-2112. , May 1; 
Treon, S., Tripsas, C., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom{\textquoteright}s macroglobulinemia [Abstract] (2011) Blood, , Abstract 2951; 
Tripsas, C.K., Meid, K., Patterson, C., Heffner, L.T., Eradat, H., Gregory, S.A., Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom{\textquoteright}s macroglobulinemia (2013) Blood, 122 (21), p. 1822. , October 21; 
Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., Ibrutinib in previously treated Waldenstrom{\textquoteright}s macroglobulinemia (2015) N Engl J Med, 372 (15), pp. 1430-1440. , Apr 9; 
Treon, S.P., How I treat Waldenstrom macroglobulinemia (2015) Blood, 126 (6), pp. 721-732. , Aug 6; 
Stone, M.J., Bogen, S.A., Role of plasmapheresis in Waldenstrom{\textquoteright}s macroglobulinemia (2013) Clin Lymphoma Myeloma Leuk, 13 (2), pp. 238-240. , Apr; 
Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with rituximab (2002) J Clin Oncol, 20 (9), pp. 2327-2333. , May 1; 
Dimopoulos, M.A., Alexanian, R., Gika, D., Anagnostopoulos, A., Zervas, C., Zomas, A., Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with rituximab: prognostic factors for response and progression (2004) Leuk Lymphoma, 45 (10), pp. 2057-2061. , Oct; 
Dimopoulos, M.A., Anagnostopoulos, A., Zervas, C., Kyrtsonis, M.C., Zomas, A., Bourantas, C., Predictive factors for response to rituximab in Waldenstrom{\textquoteright}s macroglobulinemia (2005) Clin Lymphoma, 5 (4), pp. 270-272. , Mar; 
Treon, S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan, A.R., Extended rituximab therapy in Waldenstrom{\textquoteright}s macroglobulinemia (2005) Ann Oncol, 16 (1), pp. 132-138. , Jan; 
Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom{\textquoteright}s macroglobulinemia (2001) J Immunother, 24 (3), pp. 272-279. , May{\textendash}Jun; 
Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H., Greipp, P.R., Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98) (2004) Leuk Lymphoma, 45 (10), pp. 2047-2055. , Oct; 
Dimopoulos, M.A., Zervas, C., Zomas, A., Hamilos, G., Gika, D., Efstathiou, E., Extended rituximab therapy for previously untreated patients with Waldenstrom{\textquoteright}s macroglobulinemia (2002) Clin Lymphoma, 3 (3), pp. 163-166. , Dec; 
Noronha, V., Fynan, T.M., Duffy, T., Flare in neuropathy following rituximab therapy for Waldenstrom{\textquoteright}s macroglobulinemia (2006) J Clin Oncol, 24 (1), p. e3. , Jan 1; 
Dimopoulos, M.A., Garcia-Sanz, R., Gavriatopoulou, M., Morel, P., Kyrtsonis, M.C., Michalis, E., Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) (2013) Blood, 122 (19), pp. 3276-3282. , Nov 7; 
Tesfa, D., Palmblad, J., Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms (2011) Expert Rev Hematol, 4 (6), pp. 619-625. , Dec; 
Treon, S.P., Hansen, M., Branagan, A.R., Verselis, S., Emmanouilides, C., Kimby, E., Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom{\textquoteright}s macroglobulinemia (2005) J Clin Oncol, 23 (3), pp. 474-481. , Jan 20; 
Li, S.C., Chen, Y.C., Evens, A.M., Lee, C.C., Liao, H.F., Yu, C.C., Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism (2010) Am J Hematol, 85 (10), pp. 810-812. , Oct; 
Furman, R.R., Eradat, H., Switzky, J.C., Hayman, S.R., Hofmeister, C.C., Avignon, N.A., A phase II trial of ofatumumab in subjects with Waldenstrom{\textquoteright}s macroglobulinemia (2010) ASH Annu Meet Abstr, 116 (21), p. 1795. , November 19; 
Kanan, S., Meid, K., Treon, S.P., Castillo, J.J., Clinical characteristics of rituximab intolerance in patients with Waldenstrom{\textquoteright}s macroglobulinemia (2014) Blood, 124 (21), p. 2610. , 2014-12-06 00:00:00; 
Leleu, X., Eeckhoute, J., Jia, X., Roccaro, A.M., Moreau, A.S., Farag, M., Targeting NF-kappaB in Waldenstrom macroglobulinemia (2008) Blood, 111 (10), pp. 5068-5077. , May 15; 
Roccaro, A.M., Leleu, X., Sacco, A., Jia, X., Melhem, M., Moreau, A.S., Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia (2008) Blood, 111 (9), pp. 4752-4763. , May 1; 
Sacco, A., Aujay, M., Morgan, B., Azab, A.K., Maiso, P., Liu, Y., Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom{\textquoteright}s macroglobulinemia (2011) Clin Cancer Res., 17 (7), pp. 1753-1764. , Apr 1; 
Dimopoulos, M.A., Anagnostopoulos, A., Kyrtsonis, M.C., Castritis, E., Bitsaktsis, A., Pangalis, G.A., Treatment of relapsed or refractory Waldenstrom{\textquoteright}s macroglobulinemia with bortezomib (2005) Haematologica, 90 (12), pp. 1655-1658. , Dec; 
Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Bortezomib is active in patients with untreated or relapsed Waldenstrom{\textquoteright}s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group (2007) J Clin Oncol, 25 (12), pp. 1570-1575. , Apr 20; 
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial (2010) J Clin Oncol, 28 (34), pp. 5101-5109. , Dec 1; 
Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia (2010) J Clin Oncol, 28 (8), pp. 1422-1428. , Mar 10; 
San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma (2013) J Clin Oncol, 31 (4), pp. 448-455. , Feb 1; 
Tripsas, C.K., Meid, K., Cropper, S.J., Mostyn, P., Warren, D., Paba-Prada, C.E., Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom{\textquoteright}s macroglobulinemia (2013) Blood, 122 (21), p. 757. , October 21; 
Siegel, D.S., Kaufman, J.L., Raje, N.S., Mikhael, J.R., Kapoor, P., Treon, S.P., Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenstr{\"o}m macroglobulinemia (WM) (2014) Blood, 124 (21), p. 1715. , 2014-12-06 00:00:00; 
Leblond, V., Johnson, S., Chevret, S., Copplestone, A., Rule, S., Tournilhac, O., Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma (2013) J Clin Oncol, 31 (3), pp. 301-307. , Jan 20; 
Treon, S.P., Hanzis, C., Tripsas, C., Ioakimidis, L., Patterson, C.J., Manning, R.J., Bendamustine therapy in patients with relapsed or refractory Waldenstrom{\textquoteright}s macroglobulinemia (2011) Clin lymphoma myeloma leuk, 11 (1), pp. 133-135. , Feb; 
Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., MYD88 L265P somatic mutation in Waldenstrom{\textquoteright}s macroglobulinemia (2012) N Engl J Med, 367 (9), pp. 826-833. , Aug 30; 
Dimopoulos, M.A., Trotman, J., Tedeschi, A., Matous, J.V., Macdonald, D., Tam, C., Ibrutinib therapy in rituximab-refractory patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE{\texttrademark}) (2015) Blood, 126 (23), p. 2745. , 2015-12-03 00:00:00; 
Levade, M., David, E., Garcia, C., Laurent, P.A., Cadot, S., Michallet, A.S., Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions (2014) Blood, 124 (26), pp. 3991-3995. , Dec 18; 
Gustine, J.N., Meid, K., Dubeau, T.E., Treon, S.P., Castillo, J.J., Atrial fibrillation associated with Ibrutinib in Waldenstrom{\textquoteright}s macroglobulinemia (2016) Am J Hematol, 91 (6), pp. E312-E313. , Jun; 
McMullen, J.R., Boey, E.J., Ooi, J.Y., Seymour, J.F., Keating, M.J., Tam, C.S., Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling (2014) Blood, 124 (25), pp. 3829-3830. , Dec 11; 
Dimopoulos, M.A., Zomas, A., Viniou, N.A., Grigoraki, V., Galani, E., Matsouka, C., Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with thalidomide (2001) J Clin Oncol, 19 (16), pp. 3596-3601. , Aug 15; 
Dimopoulos, M.A., Tsatalas, C., Zomas, A., Hamilos, G., Panayiotidis, P., Margaritis, D., Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone (2003) Semin Oncol, 30 (2), pp. 265-269. , Apr; 
Leleu, X., Legouill, S., Louni, C., Lionel, K., Banos, A., Arnulf, B., Lenalidomide is safe and active in Waldenstrom macroglobulinemia (WM) (2014) Blood, 124 (21), p. 4478. , 2014-12-06 00:00:00; 
Ghobrial, I.M., Witzig, T.E., Gertz, M., LaPlant, B., Hayman, S., Camoriano, J., Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia (2014) Am J Hematol, 89 (3), pp. 237-242. , Mar; 
Dimopoulos, M.A., Anagnostopoulos, A., Kyrtsonis, M.C., Zervas, K., Tsatalas, C., Kokkinis, G., Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide (2007) J Clin Oncol, 25 (22), pp. 3344-3349. , Aug 1; 
Kastritis, E., Gavriatopoulou, M., Kyrtsonis, M.C., Roussou, M., Hadjiharissi, E., Symeonidis, A., Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study (2015) Blood, 126 (11), pp. 1392-1394. , Sep 10; 
Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grunhagen, U., Losem, C., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (2013) Lancet, 381 (9873), pp. 1203-1210. , Apr 6; 
Rummel, M.J., Lerchenmuller, C., Greil, R., Gorner, M., Hensel, M., Engel, E., Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom{\textquoteright}s macroglobulinemia: results from a prospective, randomized, multicenter study (StiL NHL 7-2008 -MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214) (2012) ASH Annu Meet Abstr, 120 (21), p. 2739. , December 6; 
Tedeschi, A., Picardi, P., Ferrero, S., Benevolo, G., Margiotta Casaluci, G., Varettoni, M., Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia (2015) Leuk Lymphoma, 56 (9), pp. 2637-2642; 
Tedeschi, A., Picardi, P., Ferrero, S., Benevolo, G., Margiotta Casaluci, G., Varettoni, M., Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia (2015) Leuk Lymphoma, pp. 1-6. , Mar 14; 
Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia (2009) Blood, 113 (16), pp. 3673-3678. , Apr 16; 
Tedeschi, A., Benevolo, G., Varettoni, M., Battista, M.L., Zinzani, P.L., Visco, C., Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease (2012) Cancer, 118 (2), pp. 434-443. , Jan 15; 
Leleu, X., Soumerai, J., Roccaro, A., Hatjiharissi, E., Hunter, Z.R., Manning, R., Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs (2009) J Clin Oncol, 27 (2), pp. 250-255. , Jan 10; 
Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 (2009) J Clin Oncol, 27 (23), pp. 3830-3835. , Aug 10; 
Ghobrial, I.M., Xie, W., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia (2010) Am J Hematol, 85 (9), pp. 670-674. , Sep; 
Treon, S.P., Tripsas, C.K., Meid, K., Kanan, S., Sheehy, P., Chuma, S., Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom{\textquoteright}s macroglobulinemia (2014) Blood, 124 (4), pp. 503-510. , Jul 24; 
Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Thalidomide and rituximab in Waldenstrom macroglobulinemia (2008) Blood, 112 (12), pp. 4452-4457. , Dec 1; 
Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Lenalidomide and rituximab in Waldenstrom{\textquoteright}s macroglobulinemia (2009) Clin Cancer Res., 15 (1), pp. 355-360. , Jan 1; 
Treon, S.P., Hanzis, C., Manning, R.J., Ioakimidis, L., Patterson, C.J., Hunter, Z.R., Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen (2011) Br J Haematol, 154 (3), pp. 357-362. , Aug; 
Kyriakou, C., Canals, C., Taghipour, G., Cornelissen, J.J., Willemze, R., Socie, G., Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom macroglobulinemia (WM). An analysis of 106 cases from the European Bone Marrow Registry (EBMT) (2007) Haematologica, 92 (s2). , WM 3.9; 
Kastritis, E., Kyrtsonis, M.C., Morel, P., Gavriatopoulou, M., Hatjiharissi, E., Symeonidis, A.S., Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy (2015) Haematologica, 100 (11), pp. e446-e449. , Nov
},
	month = {2016},
	pages = {194 - 205},
	abstract = {Waldenstrom{\textquoteright}s macroglobulinaemia (WM) is a B-cell neoplasm in which bone marrow is infiltrated by lymphoplasmacytic cells that secrete monoclonal immunoglobulin M (IgM). More than a decade ago, specific criteria were agreed to define diagnosis and symptomatic disease requiring therapy; however, treatment recommendations change as new options emerge. Treatment decisions consider specific disease characteristics (burden of disease, IgM levels, presence of cytopenias) and patient characteristics (age, comorbidities, toxicity). Recently, the impact of specific mutations (in MYD88 and CXCR4) in response to specific therapies has been reported, and this may affect treatment decisions in the future. Chemo-immunotherapy combinations based on rituximab with cyclophosphamide/dexamethasone, bendamustine or bortezomib/dexamethasone are indicated for most patients. The BTK inhibitor ibrutinib was recently approved for patients with WM, and is a new option for selected newly diagnosed or relapsing patients. New B-cell receptor inhibitors, second-generation proteasome inhibitors and mammalian target of rapamycin inhibitors are promising; however, more data are needed from high-quality clinical trials. {\textcopyright} 2016 Elsevier Ltd},
	keywords = {bortezomib, Carfilzomib, Fludarabine, ibrutinib, rituximab},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994525014\&doi=10.1016\%2fj.beha.2016.08.023\&partnerID=40\&md5=3990aed3954cce0bfcc4e134cc990eb3},
	author = {Kastritis, E. and Dimopoulos, M.A.}
}
